High dose rifampicin
Phase 3Small molecule
High dose rifampicin is one of 78 small molecule programs targeting Pericarditis. It is currently in Phase 3.
3
Indications
5
Total Trials
4
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
297 competitors in Tuberculosis
#DrugCompanyPhaseTrials
1Rifadin
SanofiPhase 3
Sirturo
WWim Janssens
Phase 3
Emtriva
GileadPhase 3
Ziagen
GSKPhase 3
Levaquin
WWim Janssens
Phase 3
Sitafloxacin
Daiichi SankyoPhase 3
Tenofovir DF
GileadPhase 3
Contezolid
BBin Cao
Phase 3
High dose rifampicin
UUniversity of Cape Town
Phase 3
Isoniazid for 9 Months
NNational Taiwan University Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Tuberculosis1 trial
Tuberculosis1 trial
Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women
Not yet recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 1·NCT07069582·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for High dose rifampicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Cape Town